Conclusions
Our findings demonstrate a potent ability of mega-dose intravenous vitamin C to reverse organ dysfunction and improve the clinical state in a clinically relevant ovine model of sepsis. We also demonstrated the safety of this treatment and its benefit in a COVID-19 patient. It is now critical to complete dose-response studies in which the plasma levels of vitamin C are measured to determine the optimum dosing regimen. Further studies are necessary to determine the mechanisms by which vitamin C reverses multi-organ dysfunction in sepsis, with a focus on its anti-oxidant and anti-inflammatory actions. Such studies are essential to provide the scientific rationale for the design of large double-blinded multi-centre RCTs.